首页 > 最新文献

International journal of clinical pharmacology and therapeutics最新文献

英文 中文
Pharmacokinetics, safety, and bioequivalence of apixaban tablets in healthy Chinese subjects under fasting and fed conditions. 阿哌沙班片在中国健康受试者空腹和喂养条件下的药代动力学、安全性和生物等效性
IF 0.8 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-03-01 DOI: 10.5414/CP204299
Hong-Yu Luo, Zhen-Jiang Yao, Hui-Zhi Long, Zi-Wei Zhou, Shuo-Guo Xu, Feng-Jiao Li, Yan Cheng, Dan-Dan Wen, Ping Deng, Yue-Qing Guan, Li-Chen Gao

Objective: To evaluate the pharmacokinetics (PK), safety, and bioequivalence of two formulations of apixaban in healthy Chinese subjects under fasting and fed conditions.

Materials and methods: A single-center, randomized, open, single-dose, two-period crossover PK study was carried out under fasting and fed conditions in 64 healthy subjects enrolled in either the fasting (36 subjects) or the fed (28 subjects) arms of the study. Subjects received a single oral dose of 2.5 mg apixaban tablets as test (T) or reference (R) formulation. The primary PK parameters determined were the area under the plasma concentration-time curve from zero to t and ∞ (AUC0-t and AUC0-∞) and the maximal plasma concentration (Cmax). Safety was assessed mainly from the occurrence of adverse events (AEs).

Results: A single drop-out in the fed arm of the trial was excluded from the statistical evaluation. The 90% confidence intervals (CIs) for the geometric mean ratio (GMR) for T/R using AUC0-t were 95.4 - 100.9% and 97.8 - 103.8%, and for AUC0-∞ were 95.3 - 100.6% and 98.3 - 104.3% under fasting (36 subjects) and fed (27 subjects) conditions, respectively. Similarly, the 90% CIs for Cmax were 94.6 - 103.1% and 88.8 - 102.0% under fasting (36 subjects) and the fed (27 subjects) conditions, respectively. Therefore, the 90% CIs for the T/R AUC and Cmax ratios were within the standard range for bioequivalence (80.0 - 125.0%). There were no serious adverse events (SAEs).

Conclusion: The test and reference 2.5 mg apixaban tablets were bioequivalent and both showed good tolerability and safety.

目的:评价两种阿哌沙班制剂在空腹和喂养条件下在中国健康受试者体内的药代动力学、安全性和生物等效性。材料和方法:在禁食和进食条件下,对64名健康受试者进行了单中心、随机、开放、单剂量、两期交叉PK研究,其中36名受试者被纳入禁食组(36名受试者)或进食组(28名受试者)。受试者接受单次口服2.5 mg阿哌沙班片作为试验(T)或参考(R)配方。测定的主要PK参数为血浆浓度-时间曲线下从0到t和∞的面积(AUC0-t和AUC0-∞)和最大血浆浓度(Cmax)。安全性主要从不良事件(ae)的发生来评估。结果:在统计评价中排除了试验中单一的退出。在禁食(36例)和进食(27例)条件下,使用AUC0- T计算T/R几何平均比(GMR)的90%置信区间(ci)分别为95.4 ~ 100.9%和97.8 ~ 103.8%,AUC0-∞计算的GMR的90%置信区间(ci)分别为95.3 ~ 100.6%和98.3 ~ 104.3%。同样,在禁食(36例)和喂养(27例)条件下,Cmax的90% ci分别为94.6 ~ 103.1%和88.8 ~ 102.0%。因此,T/R AUC和Cmax比值的90% CIs均在生物等效性标准范围内(80.0 ~ 125.0%)。无严重不良事件(SAEs)。结论:本试验与参比2.5 mg阿哌沙班片生物等效,均具有良好的耐受性和安全性。
{"title":"Pharmacokinetics, safety, and bioequivalence of apixaban tablets in healthy Chinese subjects under fasting and fed conditions.","authors":"Hong-Yu Luo,&nbsp;Zhen-Jiang Yao,&nbsp;Hui-Zhi Long,&nbsp;Zi-Wei Zhou,&nbsp;Shuo-Guo Xu,&nbsp;Feng-Jiao Li,&nbsp;Yan Cheng,&nbsp;Dan-Dan Wen,&nbsp;Ping Deng,&nbsp;Yue-Qing Guan,&nbsp;Li-Chen Gao","doi":"10.5414/CP204299","DOIUrl":"https://doi.org/10.5414/CP204299","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the pharmacokinetics (PK), safety, and bioequivalence of two formulations of apixaban in healthy Chinese subjects under fasting and fed conditions.</p><p><strong>Materials and methods: </strong>A single-center, randomized, open, single-dose, two-period crossover PK study was carried out under fasting and fed conditions in 64 healthy subjects enrolled in either the fasting (36 subjects) or the fed (28 subjects) arms of the study. Subjects received a single oral dose of 2.5 mg apixaban tablets as test (T) or reference (R) formulation. The primary PK parameters determined were the area under the plasma concentration-time curve from zero to t and ∞ (AUC<sub>0-t</sub> and AUC<sub>0-∞</sub>) and the maximal plasma concentration (C<sub>max</sub>). Safety was assessed mainly from the occurrence of adverse events (AEs).</p><p><strong>Results: </strong>A single drop-out in the fed arm of the trial was excluded from the statistical evaluation. The 90% confidence intervals (CIs) for the geometric mean ratio (GMR) for T/R using AUC<sub>0-t</sub> were 95.4 - 100.9% and 97.8 - 103.8%, and for AUC<sub>0-∞</sub> were 95.3 - 100.6% and 98.3 - 104.3% under fasting (36 subjects) and fed (27 subjects) conditions, respectively. Similarly, the 90% CIs for C<sub>max</sub> were 94.6 - 103.1% and 88.8 - 102.0% under fasting (36 subjects) and the fed (27 subjects) conditions, respectively. Therefore, the 90% CIs for the T/R AUC and C<sub>max</sub> ratios were within the standard range for bioequivalence (80.0 - 125.0%). There were no serious adverse events (SAEs).</p><p><strong>Conclusion: </strong>The test and reference 2.5 mg apixaban tablets were bioequivalent and both showed good tolerability and safety.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":"61 3","pages":"129-138"},"PeriodicalIF":0.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9191055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metformin, cancer, COVID-19, and longevity. 二甲双胍、癌症、COVID-19和长寿。
IF 0.8 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-03-01 DOI: 10.5414/CP204390
Karel Kostev
{"title":"Metformin, cancer, COVID-19, and longevity.","authors":"Karel Kostev","doi":"10.5414/CP204390","DOIUrl":"https://doi.org/10.5414/CP204390","url":null,"abstract":"","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":"61 3","pages":"93-95"},"PeriodicalIF":0.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9691296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between first-step analgesic use and cancer in patients with diabetes. 糖尿病患者第一步使用镇痛药与癌症的关系。
IF 0.8 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-02-01 DOI: 10.5414/CP204305
Ie Byung Park, Hwa Jeong Seo

Objectives: This study aimed to determine the effectiveness of analgesics in inhibiting cancer development in patients with diabetes based on a sample cohort supplied by the Korean National Health Insurance Service.

Materials and methods: Regular users of analgesics included those using prescription analgesics ≥ 15 days per month at least 6 times over 2 years after the diagnosis of diabetes mellitus (baseline). The effectiveness of analgesics in patients with diabetes was evaluated using metformin adherence and three models: model 1 was adjusted for age and sex; model 2 was further adjusted for body mass index (BMI), exercise, cholesterol, hypertension, and Charlson comorbidity index (CCI); and model 3 was further adjusted for analgesics.

Results: Based on stringent extraction criteria, the sample had a cancer incidence of 4.6%. The hazard ratios of models 1 and 2 were 0.830 and 0.865, respectively. The adjusted hazard ratio for all variables, including acetaminophen and nonsteroidal anti-inflammatory drugs such as aspirin and ibuprofen, was 0.871 (model 3).

Conclusion: Regular use of analgesics by patients with diabetes decreased their risk of subsequent cancer development in this large national cohort. Compared with participants who did not develop cancer, those with cancer were older and more likely to be male, did not exercise, have more comorbidities (as assessed by CCI), and did not use analgesics regularly.

目的:本研究旨在确定镇痛药抑制糖尿病患者癌症发展的有效性,该研究基于韩国国民健康保险服务提供的样本队列。材料与方法:常规镇痛药使用者包括在诊断为糖尿病(基线)后2年内每月至少6次使用处方镇痛药≥15天的患者。采用二甲双胍依从性和三个模型来评估糖尿病患者镇痛药的有效性:模型1根据年龄和性别进行调整;模型2进一步校正体重指数(BMI)、运动、胆固醇、高血压和Charlson合并症指数(CCI);模型3进一步调整镇痛药。结果:根据严格的提取标准,样品的癌症发病率为4.6%。模型1和模型2的风险比分别为0.830和0.865。所有变量的校正风险比,包括对乙酰氨基酚和非甾体抗炎药,如阿司匹林和布洛芬,为0.871(模型3)。结论:在这个庞大的国家队列中,糖尿病患者经常使用镇痛药降低了他们随后癌症发展的风险。与未患癌症的参与者相比,患癌症的参与者年龄更大,更有可能是男性,不运动,有更多的合并症(根据CCI评估),并且没有定期使用止痛药。
{"title":"Association between first-step analgesic use and cancer in patients with diabetes.","authors":"Ie Byung Park,&nbsp;Hwa Jeong Seo","doi":"10.5414/CP204305","DOIUrl":"https://doi.org/10.5414/CP204305","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to determine the effectiveness of analgesics in inhibiting cancer development in patients with diabetes based on a sample cohort supplied by the Korean National Health Insurance Service.</p><p><strong>Materials and methods: </strong>Regular users of analgesics included those using prescription analgesics ≥ 15 days per month at least 6 times over 2 years after the diagnosis of diabetes mellitus (baseline). The effectiveness of analgesics in patients with diabetes was evaluated using metformin adherence and three models: model 1 was adjusted for age and sex; model 2 was further adjusted for body mass index (BMI), exercise, cholesterol, hypertension, and Charlson comorbidity index (CCI); and model 3 was further adjusted for analgesics.</p><p><strong>Results: </strong>Based on stringent extraction criteria, the sample had a cancer incidence of 4.6%. The hazard ratios of models 1 and 2 were 0.830 and 0.865, respectively. The adjusted hazard ratio for all variables, including acetaminophen and nonsteroidal anti-inflammatory drugs such as aspirin and ibuprofen, was 0.871 (model 3).</p><p><strong>Conclusion: </strong>Regular use of analgesics by patients with diabetes decreased their risk of subsequent cancer development in this large national cohort. Compared with participants who did not develop cancer, those with cancer were older and more likely to be male, did not exercise, have more comorbidities (as assessed by CCI), and did not use analgesics regularly.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":"61 2","pages":"67-73"},"PeriodicalIF":0.8,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9285360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Homeostasis in the microbiota and the origin of disease: A target for disease prophylaxis. 微生物群的内稳态和疾病的起源:疾病预防的目标。
IF 0.8 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-02-01 DOI: 10.5414/CPP61045
Barry G Woodcock
{"title":"Homeostasis in the microbiota and the origin of disease: A target for disease prophylaxis.","authors":"Barry G Woodcock","doi":"10.5414/CPP61045","DOIUrl":"https://doi.org/10.5414/CPP61045","url":null,"abstract":"","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":"61 2","pages":"45-47"},"PeriodicalIF":0.8,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10734455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atovaquone-induced thrombocytopenia: A case report. 阿托伐醌致血小板减少1例。
IF 0.8 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-02-01 DOI: 10.5414/CP204258
Eri Hikita, Takeo Yasu, Satoshi Chiyounabayashi, Mikio Shirota
{"title":"Atovaquone-induced thrombocytopenia: A case report.","authors":"Eri Hikita,&nbsp;Takeo Yasu,&nbsp;Satoshi Chiyounabayashi,&nbsp;Mikio Shirota","doi":"10.5414/CP204258","DOIUrl":"https://doi.org/10.5414/CP204258","url":null,"abstract":"","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":"61 2","pages":"90-92"},"PeriodicalIF":0.8,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10751609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative impact of repositioned anticancer therapies on non-cancer COVID-19 patient treatment: A systematic review and network meta-analysis of randomized controlled trials. 重新定位抗癌疗法对非癌症COVID-19患者治疗的比较影响:随机对照试验的系统评价和网络荟萃分析
IF 0.8 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-02-01 DOI: 10.5414/CP204325
Ja-Young Han, Jae-Hee Kwon, Dong Hwan Kim, Heeyoung Lee

Purpose: Coronavirus disease 2019 (COVID-19) has emerged as a serious threat to public health; anticancer-repositioning treatment strategy has been formulated to treat the disease. However, evidence supporting the efficacy and safety of repositioned anticancer treatment in treating COVID-19-infected non-cancer patients (CINPs) is limited. Therefore, this study analyzed published randomized controlled trials (RCTs) evaluating the impact of anticancer drugs compared to current standards of care (SOCs) on CINP treatment.

Materials and methods: The PubMed and Embase databases were searched to identify eligible RCTs. Outcome measures included mortality, the use of mechanical ventilation (MV), and serious adverse events (SAEs).

Results: 25 RCTs were reviewed in our study. Compared to SOCs, repositioned anticancer therapy for treating CINPs was associated with mortality reduction (odds ratio (OR) = 0.78, 95% confidence interval (CI) = 0.65 - 0.94, p = 0.01). Using the repositioned anticancer treatment exhibited statistically significant reduction, in both the number of CINPs using MV (OR = 0.67, 95% CI = 0.51 - 0.88, p = 0.004) and experiencing SAEs (OR = 0.79, 95% CI = 0.69 - 0.91, p = 0.0009).

Conclusion: Conclusively, repositioned anticancer treatment was shown significant differences from SOCs in treating CINPs, which appears to be more associated with mortality, MV use, and SAE development reduction in CINPs.

目的:2019冠状病毒病(COVID-19)已成为对公共卫生的严重威胁;制定了抗癌再定位治疗策略。然而,支持重新定位抗癌治疗治疗covid -19感染的非癌症患者(CINPs)的有效性和安全性的证据有限。因此,本研究分析了已发表的随机对照试验(rct),以评估抗癌药物与当前护理标准(soc)对CINP治疗的影响。材料和方法:检索PubMed和Embase数据库以确定符合条件的rct。结局指标包括死亡率、机械通气(MV)的使用和严重不良事件(SAEs)。结果:本研究共纳入25项随机对照试验。与soc相比,重新定位抗癌疗法治疗CINPs与死亡率降低相关(优势比(OR) = 0.78, 95%可信区间(CI) = 0.65 - 0.94, p = 0.01)。使用重新定位的抗癌治疗在使用MV的cinp (OR = 0.67, 95% CI = 0.51 - 0.88, p = 0.004)和经历SAEs (OR = 0.79, 95% CI = 0.69 - 0.91, p = 0.0009)的数量上都有统计学意义的减少。结论:总之,重新定位抗癌治疗在治疗CINPs方面与soc有显著差异,这似乎与CINPs的死亡率、MV使用和SAE发展减少更相关。
{"title":"Comparative impact of repositioned anticancer therapies on non-cancer COVID-19 patient treatment: A systematic review and network meta-analysis of randomized controlled trials.","authors":"Ja-Young Han,&nbsp;Jae-Hee Kwon,&nbsp;Dong Hwan Kim,&nbsp;Heeyoung Lee","doi":"10.5414/CP204325","DOIUrl":"https://doi.org/10.5414/CP204325","url":null,"abstract":"<p><strong>Purpose: </strong>Coronavirus disease 2019 (COVID-19) has emerged as a serious threat to public health; anticancer-repositioning treatment strategy has been formulated to treat the disease. However, evidence supporting the efficacy and safety of repositioned anticancer treatment in treating COVID-19-infected non-cancer patients (CINPs) is limited. Therefore, this study analyzed published randomized controlled trials (RCTs) evaluating the impact of anticancer drugs compared to current standards of care (SOCs) on CINP treatment.</p><p><strong>Materials and methods: </strong>The PubMed and Embase databases were searched to identify eligible RCTs. Outcome measures included mortality, the use of mechanical ventilation (MV), and serious adverse events (SAEs).</p><p><strong>Results: </strong>25 RCTs were reviewed in our study. Compared to SOCs, repositioned anticancer therapy for treating CINPs was associated with mortality reduction (odds ratio (OR) = 0.78, 95% confidence interval (CI) = 0.65 - 0.94, p = 0.01). Using the repositioned anticancer treatment exhibited statistically significant reduction, in both the number of CINPs using MV (OR = 0.67, 95% CI = 0.51 - 0.88, p = 0.004) and experiencing SAEs (OR = 0.79, 95% CI = 0.69 - 0.91, p = 0.0009).</p><p><strong>Conclusion: </strong>Conclusively, repositioned anticancer treatment was shown significant differences from SOCs in treating CINPs, which appears to be more associated with mortality, MV use, and SAE development reduction in CINPs.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":"61 2","pages":"74-89"},"PeriodicalIF":0.8,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9285361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decongestants, proton pump inhibitors, and systemic antibiotics are associated with an increased occurrence of dysbiosis. 减充血剂、质子泵抑制剂和全身性抗生素与生态失调发生率增加有关。
IF 0.8 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-02-01 DOI: 10.5414/CP204294
Seung-Young Chung, Karel Kostev, Christian Tanislav

Background: Dysbiosis (also called dysbacteriosis) is characterized by a disruption of the microbiome, resulting in an imbalance in the microbiota, changes in their functional composition and metabolic activities, and a shift in their local distribution. Dysbiosis is most commonly reported as a condition affecting the gastrointestinal tract, for example with bacterial or fungal overgrowth in the small intestine. Known causes of dysbiosis include antibiotic use, liver disease, and alcohol misuse.

Aims: To determine those variables associated with the diagnosis of dysbiosis using a national database containing data supplied by general practitioners in Germany.

Materials and methods: Patient data for the period January 2005 to December 2018 were obtained from the Disease Analyzer database (IQVIA) based on data from 1,193 general practices in Germany. Inclusion criteria were all adult patients (≥ 18 years) with an initial diagnosis of dysbiosis documented anonymously. Data for variables such as drug treatment, other diseases etc. associated with the diagnosis were analyzed using multivariable logistic regression analyses.

Results: A total of 4,013 patients diagnosed with dysbiosis and a comparative control cohort of 4,013 patients without such a dysbiosis were included in the study. The mean age in both groups was ~ 50 years where 65.2% of subjects were women. Decongestants and other nasal preparations for topical use (OR: 1.45, 95% CI: 1.14 - 1.85), proton pump inhibitors (OR: 1.39; 95% CI: 1.21 - 1.61), and systemic antibiotics (OR: 1.28, 95% CI: 1.13 - 1.47) were significantly associated with an increased occurrence of dysbiosis, whereas non-steroidal antirheumatic drugs (OR: 0.78, 95% CI: 0.69 - 0.87), lipid-lowering drugs (OR: 0.76, 95% CI: 0.63 - 0.93), and ACE inhibitors (OR: 0.64, 95% CI: 0.53 - 0.77) were associated with a decreased occurrence of dysbiosis.

Conclusion: The study provides evidence that treatment with decongestants and other nasal preparations is strongly associated with an increased occurrence of dysbiosis. Although the pathophysiology of dysbiosis is multifactorial and confounding factors cannot be ruled out, the close correlation seen may have clinical significance.

背景:生态失调(也称为细菌失调)的特征是微生物群的破坏,导致微生物群的不平衡,其功能组成和代谢活动的变化,以及其局部分布的转变。生态失调最常被报道为一种影响胃肠道的疾病,例如细菌或真菌在小肠中过度生长。已知的导致生态失调的原因包括抗生素的使用、肝脏疾病和酒精滥用。目的:利用包含德国全科医生提供的数据的国家数据库,确定与生态失调诊断相关的变量。材料和方法:2005年1月至2018年12月期间的患者数据来自疾病分析数据库(IQVIA),基于德国1193个全科医生的数据。纳入标准是所有匿名记录的初始诊断为生态失调的成年患者(≥18岁)。与诊断相关的药物治疗、其他疾病等变量数据采用多变量logistic回归分析。结果:共有4013例诊断为生态失调的患者和4013例未诊断为生态失调的患者被纳入研究。两组平均年龄在50岁左右,其中65.2%为女性。局部使用的减充血剂和其他鼻腔制剂(OR: 1.45, 95% CI: 1.14 - 1.85),质子泵抑制剂(OR: 1.39;95% CI: 1.21 - 1.61)和全身性抗生素(OR: 1.28, 95% CI: 1.13 - 1.47)与生态失调发生率的增加显著相关,而非甾体类抗风湿药物(OR: 0.78, 95% CI: 0.69 - 0.87)、降脂药物(OR: 0.76, 95% CI: 0.63 - 0.93)和ACE抑制剂(OR: 0.64, 95% CI: 0.53 - 0.77)与生态失调发生率的降低相关。结论:该研究提供的证据表明,减充血剂和其他鼻制剂的治疗与生态失调的发生率增加密切相关。虽然生态失调的病理生理是多因素的,不能排除混杂因素,但其密切的相关性可能具有临床意义。
{"title":"Decongestants, proton pump inhibitors, and systemic antibiotics are associated with an increased occurrence of dysbiosis.","authors":"Seung-Young Chung,&nbsp;Karel Kostev,&nbsp;Christian Tanislav","doi":"10.5414/CP204294","DOIUrl":"https://doi.org/10.5414/CP204294","url":null,"abstract":"<p><strong>Background: </strong>Dysbiosis (also called dysbacteriosis) is characterized by a disruption of the microbiome, resulting in an imbalance in the microbiota, changes in their functional composition and metabolic activities, and a shift in their local distribution. Dysbiosis is most commonly reported as a condition affecting the gastrointestinal tract, for example with bacterial or fungal overgrowth in the small intestine. Known causes of dysbiosis include antibiotic use, liver disease, and alcohol misuse.</p><p><strong>Aims: </strong>To determine those variables associated with the diagnosis of dysbiosis using a national database containing data supplied by general practitioners in Germany.</p><p><strong>Materials and methods: </strong>Patient data for the period January 2005 to December 2018 were obtained from the Disease Analyzer database (IQVIA) based on data from 1,193 general practices in Germany. Inclusion criteria were all adult patients (≥ 18 years) with an initial diagnosis of dysbiosis documented anonymously. Data for variables such as drug treatment, other diseases etc. associated with the diagnosis were analyzed using multivariable logistic regression analyses.</p><p><strong>Results: </strong>A total of 4,013 patients diagnosed with dysbiosis and a comparative control cohort of 4,013 patients without such a dysbiosis were included in the study. The mean age in both groups was ~ 50 years where 65.2% of subjects were women. Decongestants and other nasal preparations for topical use (OR: 1.45, 95% CI: 1.14 - 1.85), proton pump inhibitors (OR: 1.39; 95% CI: 1.21 - 1.61), and systemic antibiotics (OR: 1.28, 95% CI: 1.13 - 1.47) were significantly associated with an increased occurrence of dysbiosis, whereas non-steroidal antirheumatic drugs (OR: 0.78, 95% CI: 0.69 - 0.87), lipid-lowering drugs (OR: 0.76, 95% CI: 0.63 - 0.93), and ACE inhibitors (OR: 0.64, 95% CI: 0.53 - 0.77) were associated with a decreased occurrence of dysbiosis.</p><p><strong>Conclusion: </strong>The study provides evidence that treatment with decongestants and other nasal preparations is strongly associated with an increased occurrence of dysbiosis. Although the pathophysiology of dysbiosis is multifactorial and confounding factors cannot be ruled out, the close correlation seen may have clinical significance.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":"61 2","pages":"59-66"},"PeriodicalIF":0.8,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10741936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in the intestinal microbiota of patients with Parkinson's disease and their clinical significance. 帕金森病患者肠道菌群的变化及其临床意义
IF 0.8 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-02-01 DOI: 10.5414/CP204285
Li-Na Zhang, Wen-Ling Yuan, Ming Ye, Liang Yin, Shi-Jie Wang

Objective: To investigate the differences and their clinical significance in the intestinal microbiota in patients with Parkinson's disease (PD) in comparison to those in healthy controls.

Materials and methods: 20 patients with PD who received treatment in the First Affiliated Hospital of Bengbu Medical College between January 2019 and December 2019 were selected as the research subjects to form the PD group, while 20 age- and gender-matched healthy volunteers were selected as the control group. Fecal samples from the two groups were collected, and the V4 region of 16S-ribosomal ribonucleic acid was selected for high-throughput sequencing analysis to explore any differences, as well as their significance, in the intestinal microbiota abundance at the class, family, and genus levels between the two study groups.

Results: The operational taxonomic unit cluster analysis revealed a high degree of overlap between the patients with PD and the controls. Compared with the controls, the relative abundance of Coriobacteriia and Coriobacteriaceae was increased in the PD group (p < 0.01), while the relative abundance of Lachnospiraceae was significantly lower (p < 0.01). The relative abundance of Collinsella, Escherichia, and Fusobacterium in the PD group was significantly higher than in the control group (p < 0.05).

Conclusion: Compared with the healthy subjects, the abundance of specific microflora was significantly different in the PD patients at the class, family, and genus level. Intestinal flora may act as a potential biomarker for PD and provide a theoretical basis for microflora transplantation therapy.

目的:探讨帕金森病(PD)患者肠道菌群与健康对照组的差异及其临床意义。材料与方法:选取2019年1月至2019年12月在蚌埠医学院第一附属医院接受治疗的PD患者20例作为研究对象,组成PD组;选取年龄、性别匹配的健康志愿者20例作为对照组。收集两组粪便样本,选取16s -核糖体核糖核酸的V4区进行高通量测序分析,探讨两组在纲、科、属水平上肠道菌群丰度的差异及其意义。结果:操作分类单位聚类分析显示PD患者与对照组有高度重叠。与对照组相比,PD组的Coriobacteriia和Coriobacteriaceae相对丰度升高(p Lachnospiraceae显著降低(p Collinsella、Escherichia和Fusobacterium), PD组显著高于对照组(p结论:PD患者的特定菌群丰度在纲、科、属水平上与健康者相比存在显著差异。肠道菌群可能作为PD的潜在生物标志物,为微生物群移植治疗提供理论依据。
{"title":"Changes in the intestinal microbiota of patients with Parkinson's disease and their clinical significance.","authors":"Li-Na Zhang,&nbsp;Wen-Ling Yuan,&nbsp;Ming Ye,&nbsp;Liang Yin,&nbsp;Shi-Jie Wang","doi":"10.5414/CP204285","DOIUrl":"https://doi.org/10.5414/CP204285","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the differences and their clinical significance in the intestinal microbiota in patients with Parkinson's disease (PD) in comparison to those in healthy controls.</p><p><strong>Materials and methods: </strong>20 patients with PD who received treatment in the First Affiliated Hospital of Bengbu Medical College between January 2019 and December 2019 were selected as the research subjects to form the PD group, while 20 age- and gender-matched healthy volunteers were selected as the control group. Fecal samples from the two groups were collected, and the V4 region of 16S-ribosomal ribonucleic acid was selected for high-throughput sequencing analysis to explore any differences, as well as their significance, in the intestinal microbiota abundance at the class, family, and genus levels between the two study groups.</p><p><strong>Results: </strong>The operational taxonomic unit cluster analysis revealed a high degree of overlap between the patients with PD and the controls. Compared with the controls, the relative abundance of <i>Coriobacteriia</i> and <i>Coriobacteriaceae</i> was increased in the PD group (p < 0.01), while the relative abundance of <i>Lachnospiraceae</i> was significantly lower (p < 0.01). The relative abundance of <i>Collinsella</i>, <i>Escherichia</i>, and <i>Fusobacterium</i> in the PD group was significantly higher than in the control group (p < 0.05).</p><p><strong>Conclusion: </strong>Compared with the healthy subjects, the abundance of specific microflora was significantly different in the PD patients at the class, family, and genus level. Intestinal flora may act as a potential biomarker for PD and provide a theoretical basis for microflora transplantation therapy.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":"61 2","pages":"48-58"},"PeriodicalIF":0.8,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9300771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Efficacy and safety of belimumab in lupus nephritis: A retrospective study. 贝利木单抗对狼疮性肾炎的疗效和安全性:回顾性研究
IF 0.8 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-28 DOI: 10.5414/CP204323
Zhaowei Zhang, Jiayin Chen, Hongwei Du, Li Hua

Objective: This retrospective analysis was to examine the efficacy and safety of belimumab in lupus nephritis in China.

Materials and methods: 25 patients who were regularly followed up every 3 months in our hospital in China were included. All patients were diagnosed as having lupus nephritis and received belimumab to complement standard therapy. The primary outcomes 24-hour proteinuria, complement level, estimated glomerular filtration rate (eGFR), SELENA-SLEDAI scores, prednisone daily dose, and adverse reactions were recorded at 12, 24, 36, and 48 weeks.

Results: The SELENA-SLEDAI scores and 24-hour urine protein of the 25 patients decreased visibly from baseline 15.96 ± 3.02, 1.52 ± 1.72 to 9.52 ± 2.66 (p < 0.01), 0.5 ± 0.2 (p < 0.05) at 48 weeks, the eGFR of the 25 patients increased from 76.45 ± 22.2 to 85.48 ± 19.26 (p < 0.01) at 48 weeks, complement levels also showed a trend to increase. One patient experienced renal flare at 48 weeks, and the level of the patient's 24-hour proteinuria had been > 0.7 g at 6 months; this may be a strong predictive factor for further renal response at 12 months. Belimumab added to the standard therapy also improved the hematologic complications caused by systemic lupus erythematosus in 2 patients with a lower glucocorticoid dose. There were no serious adverse events.

Conclusion: Belimumab may be effective and safe in lupus nephritis even with regard to hematologic complications.

目的:回顾性分析贝利木单抗在中国治疗狼疮性肾炎的疗效和安全性:这项回顾性分析旨在研究在中国使用贝利木单抗治疗狼疮性肾炎的有效性和安全性。所有患者均被确诊为狼疮性肾炎,并接受了贝利木单抗作为标准疗法的补充。在12、24、36和48周时记录24小时蛋白尿、补体水平、估计肾小球滤过率(eGFR)、SELENA-SLEDAI评分、泼尼松日剂量和不良反应等主要结果:25名患者的SELENA-SLEDAI评分和24小时尿蛋白明显下降,6个月时分别从基线的15.96 ± 3.02、1.52 ± 1.72降至9.52 ± 2.66(p 0.7 g);这可能是12个月时进一步肾脏反应的有力预测因素。在标准疗法中加入贝利木单抗还能改善2名患者因系统性红斑狼疮引起的血液学并发症,同时降低糖皮质激素剂量。没有出现严重的不良反应:贝利木单抗对狼疮肾炎可能有效且安全,即使在血液学并发症方面也是如此。
{"title":"Efficacy and safety of belimumab in lupus nephritis: A retrospective study.","authors":"Zhaowei Zhang, Jiayin Chen, Hongwei Du, Li Hua","doi":"10.5414/CP204323","DOIUrl":"10.5414/CP204323","url":null,"abstract":"<p><strong>Objective: </strong>This retrospective analysis was to examine the efficacy and safety of belimumab in lupus nephritis in China.</p><p><strong>Materials and methods: </strong>25 patients who were regularly followed up every 3 months in our hospital in China were included. All patients were diagnosed as having lupus nephritis and received belimumab to complement standard therapy. The primary outcomes 24-hour proteinuria, complement level, estimated glomerular filtration rate (eGFR), SELENA-SLEDAI scores, prednisone daily dose, and adverse reactions were recorded at 12, 24, 36, and 48 weeks.</p><p><strong>Results: </strong>The SELENA-SLEDAI scores and 24-hour urine protein of the 25 patients decreased visibly from baseline 15.96 ± 3.02, 1.52 ± 1.72 to 9.52 ± 2.66 (p < 0.01), 0.5 ± 0.2 (p < 0.05) at 48 weeks, the eGFR of the 25 patients increased from 76.45 ± 22.2 to 85.48 ± 19.26 (p < 0.01) at 48 weeks, complement levels also showed a trend to increase. One patient experienced renal flare at 48 weeks, and the level of the patient's 24-hour proteinuria had been > 0.7 g at 6 months; this may be a strong predictive factor for further renal response at 12 months. Belimumab added to the standard therapy also improved the hematologic complications caused by systemic lupus erythematosus in 2 patients with a lower glucocorticoid dose. There were no serious adverse events.</p><p><strong>Conclusion: </strong>Belimumab may be effective and safe in lupus nephritis even with regard to hematologic complications.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2023-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10626038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacokinetics and bioequivalence of two methylprednisolone tablet formulations in healthy Chinese subjects under fasting and fed conditions. 两种甲基强的松龙片剂在空腹和喂养条件下的药代动力学和生物等效性。
IF 0.8 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.5414/CP204076
Lianlian Fan, Peiwen Zhang, Chunyan Gan, Qian Huang, Zhen Shen, Xue Xiao, Ying Yang, Daicong Qiu, Gang Mai, Jianzhong Shentu

Aims: The aims of this study were to evaluate and compare the pharmacokinetic profiles and bioequivalence of two tablet formulations of methylprednisolone (test formulation: Zhejiang Xianju Pharmaceutical Co., Ltd., China; reference formulation: Medrol, Pfizer Italia SRL) in healthy Chinese subjects under fasting and fed conditions.

Materials and methods: Subjects were randomly allocated to either the fasting group or the fed group and also to one of two sequences (test-reference or reference-test), according to which they received a single 16-mg dose of the test or reference methylprednisolone tablet in the study periods. Blood samples were collected pre dose and at intervals up to 16 hours after administration. Plasma methylprednisolone concentrations were determined using a validated liquid chromatography tandem mass spectrometry method. The safety of the medications was monitored throughout the study. The primary pharmacokinetic parameters measured were Cmax, AUC0-t, and AUC0-∞.

Results: A total of 56 subjects were enrolled, and all completed the study. The 90% confidence intervals for Cmax, AUC0-t, and AUC0-∞, measured under both fasting and fed conditions, fell within the acceptable range for bioequivalence of 80 - 125%. Analysis of variance showed that there were no significant differences in the primary pharmacokinetic parameters (Cmax, AUC0-t, and AUC0-∞) between the test and reference formulation measured under both fasted and fed conditions. No serious or unexpected adverse drug reactions occurred during the study period.

Conclusion: The test methylprednisolone 16 mg tablet produced in China is bioequivalent to the reference formulation (Medrol) in healthy Chinese subjects measured under both fasting and fed conditions. Both formulations were well tolerated by all study participants.

目的:评价和比较甲基强的松龙两种片剂的药代动力学特征和生物等效性(试验制剂:浙江仙居药业有限公司;参考配方:Medrol, Pfizer Italia SRL)。材料和方法:受试者被随机分配到禁食组或进食组,以及两个序列(测试-参考或参考-测试)中的一个,根据这些序列,他们在研究期间接受单次16毫克剂量的测试或参考甲基强的松龙片。在给药前和给药后16小时内采集血样。采用有效的液相色谱串联质谱法测定血浆甲基强的松龙浓度。在整个研究过程中,对药物的安全性进行了监测。测定的主要药动学参数为Cmax、AUC0-t和AUC0-∞。结果:共入组56例受试者,全部完成研究。在禁食和饲喂条件下测量的Cmax、AUC0-t和AUC0-∞的90%置信区间均在80 - 125%的生物等效性可接受范围内。方差分析显示,在禁食和喂养条件下,试验制剂与参比制剂的主要药代动力学参数(Cmax、AUC0-t和AUC0-∞)均无显著差异。研究期间未发生严重或意外的药物不良反应。结论:国产甲基强的松龙16mg试验片在空腹和进食条件下均与对照制剂美美罗具有生物等效性。两种配方均被所有研究参与者耐受良好。
{"title":"Pharmacokinetics and bioequivalence of two methylprednisolone tablet formulations in healthy Chinese subjects under fasting and fed conditions.","authors":"Lianlian Fan,&nbsp;Peiwen Zhang,&nbsp;Chunyan Gan,&nbsp;Qian Huang,&nbsp;Zhen Shen,&nbsp;Xue Xiao,&nbsp;Ying Yang,&nbsp;Daicong Qiu,&nbsp;Gang Mai,&nbsp;Jianzhong Shentu","doi":"10.5414/CP204076","DOIUrl":"https://doi.org/10.5414/CP204076","url":null,"abstract":"<p><strong>Aims: </strong>The aims of this study were to evaluate and compare the pharmacokinetic profiles and bioequivalence of two tablet formulations of methylprednisolone (test formulation: Zhejiang Xianju Pharmaceutical Co., Ltd., China; reference formulation: Medrol, Pfizer Italia SRL) in healthy Chinese subjects under fasting and fed conditions.</p><p><strong>Materials and methods: </strong>Subjects were randomly allocated to either the fasting group or the fed group and also to one of two sequences (test-reference or reference-test), according to which they received a single 16-mg dose of the test or reference methylprednisolone tablet in the study periods. Blood samples were collected pre dose and at intervals up to 16 hours after administration. Plasma methylprednisolone concentrations were determined using a validated liquid chromatography tandem mass spectrometry method. The safety of the medications was monitored throughout the study. The primary pharmacokinetic parameters measured were C<sub>max</sub>, AUC<sub>0-t</sub>, and AUC<sub>0-∞</sub>.</p><p><strong>Results: </strong>A total of 56 subjects were enrolled, and all completed the study. The 90% confidence intervals for C<sub>max</sub>, AUC<sub>0-t</sub>, and AUC<sub>0-∞</sub>, measured under both fasting and fed conditions, fell within the acceptable range for bioequivalence of 80 - 125%. Analysis of variance showed that there were no significant differences in the primary pharmacokinetic parameters (C<sub>max</sub>, AUC<sub>0-t</sub>, and AUC<sub>0-∞</sub>) between the test and reference formulation measured under both fasted and fed conditions. No serious or unexpected adverse drug reactions occurred during the study period.</p><p><strong>Conclusion: </strong>The test methylprednisolone 16 mg tablet produced in China is bioequivalent to the reference formulation (Medrol) in healthy Chinese subjects measured under both fasting and fed conditions. Both formulations were well tolerated by all study participants.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":"61 1","pages":"37-44"},"PeriodicalIF":0.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10785729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International journal of clinical pharmacology and therapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1